231 related articles for article (PubMed ID: 25894216)
1. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.
Parida S; Parekh A; Dey G; Ghosh SC; Mandal M
Cancer Biol Ther; 2015; 16(6):922-32. PubMed ID: 25894216
[TBL] [Abstract][Full Text] [Related]
2. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling.
Parida S; Pal I; Parekh A; Thakur B; Bharti R; Das S; Mandal M
Cell Death Dis; 2016 Mar; 7(3):e2154. PubMed ID: 27010855
[TBL] [Abstract][Full Text] [Related]
3. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
Wilson RJ; Giblin GM; Roomans S; Rhodes SA; Cartwright KA; Shield VJ; Brown J; Wise A; Chowdhury J; Pritchard S; Coote J; Noel LS; Kenakin T; Burns-Kurtis CL; Morrison V; Gray DW; Giles H
Br J Pharmacol; 2006 Jun; 148(3):326-39. PubMed ID: 16604093
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells.
Fujino H; Seira N; Kurata N; Araki Y; Nakamura H; Regan JW; Murayama T
Eur J Pharmacol; 2015 Dec; 768():149-59. PubMed ID: 26518053
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Majumder M; Xin X; Liu L; Girish GV; Lala PK
Cancer Sci; 2014 Sep; 105(9):1142-51. PubMed ID: 24981602
[TBL] [Abstract][Full Text] [Related]
6. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
7. Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.
Yoshida K; Fujino H; Otake S; Seira N; Regan JW; Murayama T
Eur J Pharmacol; 2013 Oct; 718(1-3):408-17. PubMed ID: 23973650
[TBL] [Abstract][Full Text] [Related]
8. Activation of prostaglandin EP4 receptor attenuates the induction of cyclooxygenase-2 expression by EP2 receptor activation in human amnion fibroblasts: implications for parturition.
Lu JW; Wang WS; Zhou Q; Gan XW; Myatt L; Sun K
FASEB J; 2019 Jul; 33(7):8148-8160. PubMed ID: 30917001
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells.
Hsu HH; Lin YM; Shen CY; Shibu MA; Li SY; Chang SH; Lin CC; Chen RJ; Viswanadha VP; Shih HN; Huang CY
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28587064
[TBL] [Abstract][Full Text] [Related]
10. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation.
Mendez M; LaPointe MC
Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2111-7. PubMed ID: 15626689
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP‑PKA/PI3K‑Akt signaling pathway.
Xu S; Zhou W; Ge J; Zhang Z
Mol Med Rep; 2018 Mar; 17(3):4702-4712. PubMed ID: 29328471
[TBL] [Abstract][Full Text] [Related]
12. EP
Bradbury P; Rumzhum NN; Ammit AJ
J Cell Physiol; 2019 Jul; 234(7):11070-11077. PubMed ID: 30536718
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
14. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism.
Schmidt A; Sinnett-Smith J; Young S; Chang HH; Hines OJ; Dawson DW; Rozengurt E; Eibl G
Surgery; 2017 Jun; 161(6):1570-1578. PubMed ID: 28222855
[TBL] [Abstract][Full Text] [Related]
15. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
Majumder M; Landman E; Liu L; Hess D; Lala PK
Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation.
Takahashi T; Uehara H; Ogawa H; Umemoto H; Bando Y; Izumi K
Oncotarget; 2015 Mar; 6(7):4829-44. PubMed ID: 25638159
[TBL] [Abstract][Full Text] [Related]
17. The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest, and inhibits prostaglandin E2-induced proliferation in oral squamous carcinoma Tca8113 cells.
Li X; Yang B; Han G; Li W
J Oral Pathol Med; 2017 Nov; 46(10):991-997. PubMed ID: 28342204
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
Robertson FM; Simeone AM; Lucci A; McMurray JS; Ghosh S; Cristofanilli M
Cancer; 2010 Jun; 116(11 Suppl):2806-14. PubMed ID: 20503412
[TBL] [Abstract][Full Text] [Related]
19. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Xin X; Majumder M; Girish GV; Mohindra V; Maruyama T; Lala PK
Lab Invest; 2012 Aug; 92(8):1115-28. PubMed ID: 22641101
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.
Bonfill-Teixidor E; Otxoa-de-Amezaga A; Font-Nieves M; Sans-Fons MG; Planas AM
J Neuroinflammation; 2017 Jan; 14(1):3. PubMed ID: 28086956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
